OssDsign Appoints Simon Cartmell as Chairman of the Board
Strengthens Organization Ahead of the US Launch of Its Novel Regenerative Facial and Cranial Implants in 2017
UPPSALA, SWEDEN, April 20, 2016 (Newswire.com) - OssDsign AB, a Swedish designer, manufacturer and distributor of next generation implants for cranial and facial repair, today announced the appointment of Simon Cartmell as Chairman of the Board. Mr. Cartmell is an experienced entrepreneur in the life-sciences industry and a Non-Executive Director/Chairman of a number European medical device companies.
Mr. Cartmell was previously the CEO and architect behind the commercial success of ApaTech, a British medtech firm that developed ACTIFUSE, a novel bone void filler used to treat bone defects resulting from orthopaedic and spine surgery or traumatic injury. ApaTech was acquired by Baxter International in March 2010 for $330 million.
“I have been very impressed by both OssDsign’s cutting-edge regenerative implants and the team behind the technology,” says Mr. Cartmell, “OssDsign has clearly differentiated products, a very promising technology platform and is about to enter an exciting phase in its development. I see many similarities with my previous successes in the medtech sector, and I am looking forward to working with the rest of the board and the newly expanded management team to make OssDsign’s regenerative implants a global success.”
“We are extremely happy to have Simon join OssDsign,” says Dr. Victor Drvota, Chief Investment Officer at Karolinska Development, the founding investor in the company. Dr. Drvota continues: “His experience of global, and in particular, US commercialization within the field of orthopedic biomaterials gives us an important strategic edge. We regard Simon’s decision to become OssDsign’s Chairman as a clear endorsement of the benefits that company’s regenerative implants deliver and their significant commercial potential.”
OssDsign is now entering a phase of global expansion and anticipates its first US product launch in the first quarter of 2017. OssDsign has already successfully commercialized its lead products OSSDSIGN® Cranial and OSSDSIGN® Facial on the UK, German and Scandinavian markets. OssDsign raised €9.6 million to support its growth ambitions in November 2015.
As part of the rapid transformation into a globally operating company, OssDsign also welcomes Rick Thomas to the new role of VP Global Commercial Operations. Mr. Thomas brings invaluable experience from previous positions in sales and marketing at Medtronic, ApaTech and Baxter, where he last served as International Sales Director.
Further key recruitments to OssDsign include Claes Lindblad, Chief Financial Officer; Henrik Hjort, Marketing Director; Ulrik Birgersson, Head of Clinical Engineering and Kajsa Björklund, Manufacturing Manager.
Anders Lundqvist, CEO of OssDsign, commenting on today’s announcement said, “I am delighted that Simon has agreed to become our Chairman as we enter a key period for OssDsign. With our strengthened management team, all of whom have broad backgrounds within the international medical device industry, I believe we are now well placed to successfully transition from a development stage company into a business with commercial operations in the US and Europe that will allow us to drive the sales of our unique regenerative implants.”
For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Phone: +46 73 206 98 08, email: al@ossdsign.com
About OssDsign
OssDsign is a Swedish medtech company dedicated to creating regenerative implants for improved healing of bone defects and deficits in skull, facial and other types of surgery. OssDsign has successfully launched its first patient specific products OSSDSIGN® Cranial and OSSDSIGN® Facial in Germany, the UK and the Nordic countries, and further global market expansion is ongoing.
By combining clinical insight with proprietary material technology and patient adapted design, OssDsign supplies an expanding range of tailored solutions for cranial repair and facial bone reconstruction. OssDsign’s technology is the result of collaboration between clinical researchers at the Karolinska University Hospital, Stockholm, and material science experts at the Ångström Laboratory at Uppsala University. Main investors in OssDsign are Karolinska Development, SEB Venture Capital, Fouriertransform and Almi Invest.
Source: OssDsign AB
